Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

One company value investors might notice is Viatris (VTRS). VTRS is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. Value investors also love the P/S ratio, which is ...

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as ...

This leaflet answers some common questions about Montelukast Viatris. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other stocks. Wall Street’s main indices all finished in the green territory on Wednesday ...

In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other best medical stocks under $20. The medical industry plays a crucial role in ensuring the ...

Valued at a market cap of $14.8 billion, Viatris Inc. (VTRS) is a healthcare company that operates in four segments: developed markets, Greater China, JANZ, and emerging markets. Based in ...

Viatris says local production of antiretrovirals will further strengthen South Africa’s healthcare infrastructure. South African health bodies applaud this as a step in the right direction but ...

Viatris disclosed that its manufacturing facility in Indore, India, was issued a warning letter from the FDA, which banned 11 products that are produced at the site from being imported into the U ...

Viatris (VTRS) issued the following statement: “Our plants around the world are regularly inspected by health authorities to ensure compliance with the various markets we serve. Following an ...